Abstract:A differential mobility spectrometry (DMS) in combination with a multiple ion monitoring (MIM) method was developed and validated for quantitative LC-MS/MS bioanalysis of pasireotide (SOM230) in human plasma. Pasireotide, a therapeutic cyclic peptide, exhibits poor collision-induced dissociation (CID) efficiency for multiple reaction monitoring (MRM) detection. Therefore, in an effort to increase the overall sensitivity of the assay, a DMS-MIM approach was explored. By selecting the most abundant doubly charged precursor ion in both the Q1 and Q3 of the mass analyzer in MIM and combining the DMS capability to significantly reduce the high matrix/chemical background noise, this new LC-DMS-MIM method overcomes the sensitivity challenge in the typical MRM method due to poor CID fragmentation of the analyte. Human plasma was spiked with pasireotide with concentrations in the range 0.01-50 ng/mL. Weak cation-exchange solid-phase extraction was employed for sample preparation. The sample extracts were analyzed with a SCIEX QTRAP 6500 system equipped with an ESI source and DMS device. The separation voltage and compensation voltage of the DMS and other parameters of the MS system were optimized to maximize signal responses. The performance of the LC-DMS-MIM assay for quantitative analysis of pasireotide in human plasma was evaluated and compared to those obtained via LC-MRM and LC-MIM without DMS. Overall, the assay sensitivity with DMS-MIM was approximately 5-fold better than that observed in MRM or MIM without DMS. The assay was validated with accuracy (% bias) and precision (% CV) of the QC results at eight concentration levels (0.01, 0.02, 0.05, 0.15, 0.3, 1.5, 15, and 37.5 ng/mL) evaluated ranging from -4.8 to 5.0% bias and 0.7 to 8.6% CV for the intraday and interday runs. The current LC-DMS-MIM workflow can be expanded to quantitative analysis of other molecules that have poor fragmentation efficiency in CID.

Differential Mobility Spectrometry Followed by Tandem Mass Spectrometry with Multiple Ion Monitoring for Bioanalysis of Eptifibatide in Rat Plasma.

Differential Mobility Spectrometry Coupled with Multiple Ion Monitoring in Regulated LC-MS/MS Bioanalysis of a Therapeutic Cyclic Peptide in Human Plasma

Optimization of Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous Determination of Capilliposide B and Its Active Metabolite in Rat Urine and Feces: Overcoming Nonspecific Binding.

Development and Validation of a Liquid Chromatography/tandem Mass Spectrometry Assay for the Simultaneous Determination of Dabigatran Etexilate, Intermediate Metabolite and Dabigatran in 50μl Rat Plasma and Its Application to Pharmacokinetic Study.

A Rugged and Accurate Liquid Chromatography–tandem Mass Spectrometry Method for Quantitative Determination of BMS-790052 in Plasma

Optimized LC-MS/MS method for quantifying insulin degludec and liraglutide in rat plasma and Tissues: Application in pharmacokinetics and biodistribution

Liquid Chromatography Tandem Mass Spectrometric Method for Quantification of Margetuximab in Rat Plasma and Application to a Pharmacokinetic Study

Efficient use of retention time for the analysis of 302 drugs in equine plasma by liquid chromatography-MS/MS with scheduled multiple reaction monitoring and instant library searching for doping control

Simultaneous quantification of icaritin and its novel 3-methylcarbamate prodrug in rat plasma using HPLC-MS/MS and its application to pharmacokinetic study

Bioavailability and Pharmacokinetic Study of Tirofiban in Rat by Liquid Chromatography Mass Spectrometry

Development and validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for benvitimod quantification in human plasma

Quantification of Axitinib After Oral and Intravenous Administration in Rats by UPLC-MS/MS: Application to the Pharmacokinetic Study

Simultaneous Quantification of Multiple Active Components from Xiexin Decoction in Rat Plasma by Lc-Esi-Ms/Ms: Application in Pharmacokinetics

Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.

LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma.

A High-Sensitivity Lc-Ms/Ms Method for the Determination of 4-Methyl-piperazine-1-carbodithioc Acid 3-Cyano-3, 3-Diphenylpropyl Ester Hydrochloride in Rat Plasma and Its Application to A Pharmacokinetics Study

[Pharmacokinetics of Epirubicin Hydrochloride Long-Circulating Thermosensitive Liposomes in Rat Plasma].

Quantification of CPT13 in rat plasma using LC–MS/MS for a pharmacokinetic study

Differential Mobility Spectrometry-Tandem Mass Spectrometry with Multiple Ion Monitoring Coupled with in Source-Collision Induced Dissociation: A New Strategy for the Quantitative Analysis of Pharmaceutical Polymer Excipients in Rat Plasma

Quantitation of Bivalirudin, a Novel Anticoagulant Peptide, in Human Plasma by LC-MS/MS： Method Development, Validation and Application to Pharmacokinetics

Simultaneous Determination of Ibrutinib and its Active Metabolite PCI-45227 in Rat Plasma by HPLC-UV: Its Pharmacokinetic Application